
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Zoetis Inc (ZTS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZTS (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $190.62
1 Year Target Price $190.62
10 | Strong Buy |
4 | Buy |
5 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.17% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 67.83B USD | Price to earnings Ratio 26.34 | 1Y Target Price 190.62 |
Price to earnings Ratio 26.34 | 1Y Target Price 190.62 | ||
Volume (30-day avg) 19 | Beta 0.88 | 52 Weeks Range 138.76 - 197.91 | Updated Date 08/14/2025 |
52 Weeks Range 138.76 - 197.91 | Updated Date 08/14/2025 | ||
Dividends yield (FY) 1.22% | Basic EPS (TTM) 5.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 1.62 | Actual 1.76 |
Profitability
Profit Margin 27.83% | Operating Margin (TTM) 40.2% |
Management Effectiveness
Return on Assets (TTM) 15.37% | Return on Equity (TTM) 52.77% |
Valuation
Trailing PE 26.34 | Forward PE 24.45 | Enterprise Value 72914888471 | Price to Sales(TTM) 7.23 |
Enterprise Value 72914888471 | Price to Sales(TTM) 7.23 | ||
Enterprise Value to Revenue 7.77 | Enterprise Value to EBITDA 18.14 | Shares Outstanding 443183008 | Shares Floating 442368014 |
Shares Outstanding 443183008 | Shares Floating 442368014 | ||
Percent Insiders 0.09 | Percent Institutions 97.26 |
Upturn AI SWOT
Zoetis Inc

Company Overview
History and Background
Zoetis Inc. was founded in 1952 as the animal health division of Pfizer. In 2013, it was spun off as an independent publicly traded company. It has grown through acquisitions and organic growth to become the world's largest producer of medicine and vaccinations for pets and livestock.
Core Business Areas
- Livestock: Develops, manufactures and commercializes a variety of products for livestock, including cattle, swine, poultry and fish, used to prevent and treat disease and enhance animal health and productivity.
- Companion Animal: Develops, manufactures and commercializes a variety of products for companion animals, including dogs, cats and horses, used to prevent and treat disease and enhance animal health and quality of life.
Leadership and Structure
Kristin Peck is the CEO of Zoetis. The company has a board of directors and is structured into different business units based on species and geography.
Top Products and Market Share
Key Offerings
- Simparica Trio: A parasiticide for dogs that protects against heartworm disease, fleas and ticks, and roundworms and hookworms. It has a significant market share in the companion animal parasiticides market. Competitors include Bravecto (Merck) and NexGard (Boehringer Ingelheim).
- Draxxin: An injectable antibiotic used to treat bovine respiratory disease (BRD) in cattle. It is a leading product in the livestock segment. Competitors include Baytril (Bayer) and Micotil (Elanco).
- Cytopoint: An injectable monoclonal antibody therapy for allergic dermatitis in dogs. Cytopoint is a blockbuster product driving significant revenue. Competitors are Apoquel (Zoetis) and Atopica (Elanco).
Market Dynamics
Industry Overview
The animal health industry is growing due to increasing pet ownership, rising demand for animal protein, and growing awareness of animal health and welfare. This results in increased spending on animal medication. Consolidation is occurring and global demand is rising.
Positioning
Zoetis is the largest animal health company globally, holding a leading position in both livestock and companion animal segments. The company's competitive advantages include its broad product portfolio, global presence, strong R&D capabilities, and established relationships with veterinarians and livestock producers.
Total Addressable Market (TAM)
The global animal health market is estimated to be over $50 billion. Zoetis is positioned to capture a substantial share of this TAM through its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Global market leader
- Broad product portfolio
- Strong R&D capabilities
- Established distribution network
- Strong brand reputation
Weaknesses
- Dependence on acquisitions for growth
- Exposure to currency fluctuations
- Regulatory risks
- Pricing pressure in some markets
Opportunities
- Expanding into emerging markets
- Developing innovative products and services
- Leveraging digital technologies
- Acquiring smaller animal health companies
Threats
- Increasing competition
- Generic erosion of key products
- Economic downturns
- Changing consumer preferences
Competitors and Market Share
Key Competitors
- ELAN
- MRK
- BMY
Competitive Landscape
Zoetis has a competitive advantage due to its size, scale, and diversified product portfolio. However, it faces competition from other major animal health companies like Elanco, Merck and Boehringer Ingelheim.
Major Acquisitions
Jurox
- Year: 2022
- Acquisition Price (USD millions): 506
- Strategic Rationale: Expanded Zoetis' presence in the companion animal and livestock markets, particularly in Australia, New Zealand, and Canada.
Basepaws
- Year: 2022
- Acquisition Price (USD millions):
- Strategic Rationale: Basepaws is a pet genetics company focused on microbiome, genetics and nutritional testing. This acquisition enables Zoetis to expand its portfolio into precision animal health.
Growth Trajectory and Initiatives
Historical Growth: Zoetis has demonstrated consistent revenue and earnings growth over the past several years, driven by organic growth and strategic acquisitions.
Future Projections: Analysts project continued growth for Zoetis, driven by increasing demand for animal health products and the company's strong market position.
Recent Initiatives: Recent strategic initiatives include expanding into new markets, developing innovative products, and investing in digital technologies.
Summary
Zoetis is a strong company due to its global market leadership and product offerings. They are growing and producing value for shareholders. The competitive nature of the market will test the company in the future, however, as they will face price pressure. Currency fluctuations and regulatory risks may also pose a future threat to Zoetis.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Zoetis Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Financial News Articles
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zoetis Inc
Exchange NYSE | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2013-02-01 | CEO & Director Ms. Kristin C. Peck | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13800 | Website https://www.zoetis.com |
Full time employees 13800 | Website https://www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.